Kymera Therapeutics clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   BREADTH-EXT · KT-621 Administered Orally to · Asthma Previously…BREADTH-EXT · KT-621 Administered Orally to · Asthma Previously Enrolled in a KT-621 Asthma Study

   Trial sites expanded: 1 → 7 locations

   Kymera Therapeutics, Inc.·Phase 2· NCT07677059· Registry history of NCT07677059 on ClinicalTrials.gov (opens the registry)

   Updated Oct 7, 2026

2. Minor

   BROADEN2 · KT-621 Administered Orally to · Moderate to Severe…BROADEN2 · KT-621 Administered Orally to · Moderate to Severe Atopic Dermatitis

   Trial sites reduced: 68 → 61 locations

   Kymera Therapeutics, Inc.·Phase 2· NCT07217015· Registry history of NCT07217015 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

3. Minor

   BREADTH · KT-621 Administered Orally to Adult · Moderate to…BREADTH · KT-621 Administered Orally to Adult · Moderate to Severe Eosinophilic Asthma

   Trial sites expanded: 71 → 81 locations

   Kymera Therapeutics, Inc.·Phase 2· NCT07323654· Registry history of NCT07323654 on ClinicalTrials.gov (opens the registry)

   Updated Oct 6, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.